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Because of the imbalance in the supply and demand of red blood cells (RBCs), especially for alloimmunized patients or
patients with rare blood phenotypes, extensive research has been done to generate therapeutic quantities of mature RBCs from
hematopoietic stem cells of various sources, such as bone marrow, peripheral blood, and cord blood. Since human embryonic
stem cells (hESCs) and induced pluripotent stem cells (iPSCs) can be maintained indeﬁnitely in vitro, they represent potentially
inexhaustible sources of donor-free RBCs. In contrast to other ex vivo stem-cell-derived cellular therapeutics, tumorigenesis is not
a concern, as RBCs can be irradiated without marked adverse eﬀects on in vivo function. Here, we provide a comprehensive review
of the recent publications relevant to the generation and characterization of hESC- and iPSC-derived erythroid cells and discuss
challenges to be met before the eventual realization of clinical usage of these cells.
1.Introduction
Medical progress, speciﬁcally in the ﬁelds of hematol-
ogy/oncology and transplantation surgery, as well as an over-
all aging population, has led to an ever-increasing demand
for erythrocytes for transfusion to currently approximately
ﬁfty thousand RBC concentrates per million population
per year in countries with a high standard of health care.
Currently, the exclusive source for these is volunteer donors,
who obviously are subject to the same societal changes as
the recipients, that is, they are aging also. Recruitment of
new donors from the shrinking pool of eligible individuals
is challenging and additionally hampered by ever-increasing
restrictions, predominantly recipient-directed exclusion cri-
teria for donors. Perceived lack of safety of blood products
also is a highly sensitive issue in the population, particularly
since the emergence of HIV in the eighties, as a consequence
of which a whole generation of hemophilia patients was
infected. The desire to counter these challenges has led to the
extensive eﬀort in the generation of red blood cells (RBCs)
i nv i t r of r o mav a r i e t yo fs o u r c e s ,s u c ha sb o n em a r r o w ,
peripheral blood, and cord blood. More recently, utilizing
embryonic stem cells (hESCs) and induced pluripotent stem
cells (iPSCs) to generate universal donor RBCs has been
envisioned [1, 2].
hESCs are pluripotent stem cells derived from the inner
cell mass of the blastocyst [3], and iPSCs are ESC-like cells
generated by reprogramming somatic cells, most often via
forced expression of a combination of transcription factors,
such as Oct3/4, Nanog, KLF4, c-Myc, LIN28, and SOX2
[4,5].BothhESCsandhiPSCscanbemaintainedindeﬁnitely
in culture and can be induced to undergo diﬀerentiation
to give rise to any cell types of all three germ layers. These
characteristics made them not only a valuable tool for the
study of developmental biology, but also a potential source
forproviding unlimited numbers of cellsfor cellreplacement2 Stem Cells International
therapies. While our laboratory has previously shown that
the then existing hESC lines are not conducive to culturing
universal donor RBCs [6], many additional hESC lines have
been generated ever since. Furthermore, the recent advances
inhiPSCshavepartiallyobviatedthisobstacle,asexempliﬁed
bythegenerationofhiPSCsfromaBombayindividualwhose
RBCs lack ABH antigens expression due to the absence of
the H gene (FUT1-) and Secretor gene (FUT2-) encoded α
1,2 fucosyltransferase activities [7]. It has been proposed by
French researchers that based on their database, as few as 15
hiPSC clones would cover 100% of the needs of allCaucasian
patients with rare blood phenotypes/genotypes in France
[2]. In addition, they suggested that one single hiPSC clone
wouldmeet73%oftheneedsinalloimmunizedpatientswith
sickle cell disease for whom rare cryopreserved RBC units
are required [2]. In this review, we summarize the recent
development in the in vitro generation and characterization
of erythroid cells from either hESCs or iPSCs and point out
areas of further investigation needed before their use for
clinical purposes.
2. Methods for the Generation of
ErythroidCellsfrom hESCsandiPSCs
hESCs and hiPSCs represent renewable, potentially unlim-
ited cell sources, in contrast to the hematopoietic stem cells
originating from bone marrow, cord blood, or peripheral
blood,thatrequiredonorstobeconstantlysecured,fortheex
vivo generation of RBCs. The potential charm of autologous
hiPSCs in the context of erythrocyte generation is the
identical genetic identity between the cells and the recipient
for all blood group antigens, since the prevalent clinical
problem is the polysensitization against foreign erythrocyte
antigens, and these patients are at risk for acquisition of
additional antibodies. Several laboratories have established
protocols to derive erythroid cells from the hESCs and
hiPSCs. While each protocol varies in technical details, they
can generally be divided into two main categories: those
that coculture stem cells with stromal layers to induce
hematopoietic diﬀerentiation, and those that culture stem
cells in suspension to form embryoid bodies (EBs) (Table 1).
OneexceptionisarecentreportbySalvagiottoandcolleagues
who circumvent EBs and stromal coculture by utilizing a
matrix protein to generate a 2-dimentioinal culture system
to support the generation of hematopoietic cells from hESCs
and hiPSCs [25].
2.1. Stromal Coculture. Several types of stromal layers have
been reported in the coculture system, including murine
bone marrow (BM) cell line S17 [9, 26] and OP9 [8, 10, 27],
the yolk sac endothelial cell line C166 [9], murine fetal liver-
derived stromal line (mFLSC) [12, 13], murine aorta-gonad-
mesonephros (AGM) stromal lines [12], primary murine
stromal cells from AGM and FL [12], immortalized human
fetal liver hepatocyte line FH-B-hTERT [1, 14, 15], and
primary human stromal cells derived from aorta- AGM, FL,
and fetal BM (FBM) [11]. A side-by-side comparison ﬁnds
that FH-B-hTERT cells are more eﬀective than S17 cells in
stimulating CD34+ cells generation from hESCs [14]. The
direct contact with stromal layers increases hematopoietic
diﬀerentiation eﬃciency [11, 12, 26], although it is not
an absolute requirement [11, 26]. In general, when culture
media are supplemented with fetal bovine serum (FBS),
no additional growth factors are required during coculture
[1, 9, 12, 14, 15, 26]. To generate large quantities of relatively
pure erythroid cells, often a further puriﬁcation of CD34+
cells from the coculture population is performed prior to
seedingtheminmediasupplementedwithgrowthfactorsfor
erythroidexpansion[1,8],orthemixtureofcoculturecellsis
placed in methylcellulose cultures for hematopoietic colony
assays, and then individual erythroid colonies are extracted
from semisolid culture for further analysis [13]. While these
studies have provided important insights into the erythroid
development from hESCs or hiPSCs and have the potential
for large-scale production [1, 8, 13], the utilization of
murine cells in coculture by some protocols may make them
unsuitable for clinical applications in the future.
2.2. EB Formation. Alternatively, successful hematopoietic
induction can be achieved by EB formation, usually by plac-
ing clumps of hESCs or hiPSCs in nontissue culture-treated
plates, or ultralow attachment plates. It has been reported in
mouse EBs that cells undergo self-organization to establish
anteroposterior polarity and form a primitive streak-like
region via the Wnt signaling pathway [28]. For robust
hematopoietic diﬀerentiation, good quality EB formation is
essential. While Lu et al. observe that it is essential to use
high-qualityhESCswithminimalsignsofdiﬀerentiationand
uniform stem cell marker expression for EBs formation and
for high-eﬃciency erythroid generation [22], Ungrin and
colleagues ﬁnd that aggregates formed from populations of
cells with the highest levels of Oct4 actually exhibit the least
stabilityintermsofEBformation[29].WeﬁndthathESCsor
hiPSCs cultured under murine embryonic ﬁbroblast (MEF)
feeder-free conditions on matrigel-coated plates with MEF-
conditioned media or a chemically deﬁned media, such as
mTeSR (StemCell Technologies), can also be used for EB
formation, although they tend to be more temperamental
with less consistent EB formation for unknown reasons
(unpublished data). EB formation can be further controlled
by plating a deﬁned number of cells in untreated U bottom
or V bottom, 96- or 386-well plates, or AggreWells and
forcing the formation of aggregates by centrifugation [30,
31]. Because the forced aggregation of a deﬁned number
of hESCs or hiPSCs requires the generation of single cell
suspensions prior to aggregation, we ﬁnd that the addition
of p160-Rho-associated coiled coil kinase (ROCK) inhibitor
Y-27632beforeandduringtheﬁrst24hoursofEBformation
is essential for the survival of these stem cells, consistent with
previous reports [29, 32]. However, while forced aggregation
leads to uniformly sized EBs, it has been shown that in
fact, the traditional suspension culture of placing clumps of
hESCsdirectlyintolow-attachmentplatesgeneratesEBswith
higher levels of hematopoietic diﬀerentiation than forced
aggregation or hanging drop culture does [33]. Regardless
of the EB formation method employed, it is importantStem Cells International 3
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to note that care should be taken to avoid fusion among
individual EBs as active migration of cells and the expression
of transcription factor Cd×2, known for its role in aﬀecting
cell fate decisions [34], have been observed in a subset
of cells at the junction of fusing EBs [29]. While housing
individual EBs in separate wells can prevent the aggregation,
it is not recommended, as the paracrine eﬀect enhances
hematopoietic diﬀerentiation of EBs [33]. Encapsulating
them in size-speciﬁed agarose capsules [35]m a yp r o v i d e
an alternative, although the hematopoietic diﬀerentiation of
encapsulated EBs has not been fully examined.
An array of media has been used for the generation of
EBs. Our laboratory has routinely used a medium essentially
composed of Iscove’s Modiﬁed Dulbecco’s Media, fetal
bovine serum (FBS), and protein-free hybridoma medium.
Originally,weincludedbasicﬁbroblastgrowthfactor(bFGF)
and vascular endothelial growth factor (VEGF) in the
medium [17] and later found them to be unnecessary in
FBS-supplemented media, although VEGF-165 has been
reported to augment erythropoiesis during EB formation
[16]. Lot speciﬁc eﬀects of FBS on hematopoietic diﬀer-
entiation during EB formation have been noted and thus
require prescreening of FBS for the EB assay (unpublished
observations). Several laboratories have established serum-
free media for EB formation, in which growth factor sup-
plementation is required [26]. Bone morphogenetic protein
4 (BMP4), VEGF, granulocyte colony-stimulating factor (G-
CSF),interleukin-3(IL-3),stemcellfactor(SCF),Flt3ligand,
IL-6, insulin-like growth factor-2 (IGF-II), thrombopoietin
(TPO),andbFGFhavebeenusedinanassortmentofcombi-
nationstoachieveinductionofhematopoieticdiﬀerentiation
of EBs [22, 26, 30, 33, 36, 37]. A recent publication utilizing
human plasma ﬁnds the addition of BMP4 and VEGF to
be indispensable, consistent with the ﬁnding by Tian and
colleagues [26], and the inclusion of SCF, TPO, Flt3 ligand,
erythropoietin(EPO),IL-3,andIL-6intheEBmediumgives
the optimal erythropoietic stimulation [20].
2.3. From EBs to Erythroid Cells. Diﬀerent laboratories har-
vest EBs at diﬀerent time points for further erythroid
diﬀerentiation. Our protocol originally included an adher-
ent culture step for erythroid induction, but was later
streamlined to seeding dissociated day-7 EBs directly into
a serum-free erythroid induction medium in which a large
number of relatively pure erythroid cells (>90%) can be
obtained with 21 days of total culture time [17–19]. We ﬁnd
that EPO and SCF are absolutely required for the survival
and diﬀerentiation of erythroid progenitors in EBs; IL-3
and IL-6 augment the expansion of erythroid cells, but
G-CSF and GM-CSF are dispensable (unpublished data),
similar to the conclusion of others [10]. If added, FBS has
signiﬁcant inhibitory eﬀect on the growth and expansion of
these erythroid progenitors from EBs, as previously noted
by Zambidis et al. [21]. Furthermore, while dissociated
day-7 EBs give rise to almost exclusively erythroid cells
(>90%) in the serum-free erythroid induction medium, day-
14 EBs generate a mixture of erythroid and myeloid cells
[17]. Interestingly, while ∼5–10% cells of hESC line H1-
derived EBs express glycophorin-A between 7 and 14 days
in our FBS-based system [17, 19], very little glycophorin-
A expression is detected in the H1-derived EBs up to 20
days in the human plasma-based cultures in spite of the
hematopoietic cytokines supplementation in the medium
[20]. The diﬀerences in culture time and cytokine sup-
plements notwithstanding, Lapillonne et al. also ﬁnd the
unpuriﬁed, dissociated EBs from their human plasma-based
cultures generating exclusively erythroid cells when placed in
an erythroid expansion medium that also contains human
plasma. Lu and colleagues take a diﬀerent approach by
placingdissociatedday-3.5EBsinblast-colonygrowthmedia
with the addition of bFGF and recombinant tPTD-HoxB4
fusion protein to expand hemangioblasts prior to transfer
into an erythroid diﬀerentiation and expansion culture [22].
A mixture of erythroid and nonerythroid cells is apparently
obtained, which requires an overnight adhesion culture to
remove nonerythroid cells.
2.4. From Erythroblasts to RBCs. Extended ex vivo propaga-
tion of cells is associated with acquisition of genetic alter-
ations, including transformation. Safety concerns about in
vivo use of such cells therefore have been raised, speciﬁcally
in the autologous setting. As terminally diﬀerentiated (and
physiologically enucleated) cells, in this respect, erythrocytes
possess considerable advantages over transplants of imma-
ture cells or cells with proliferative capacity in spite of their
maturity, such as T cells. Several studies show that hESC-
and hiPSC-derived erythroblasts are capable of enucleation
and become fully mature RBCs. A prolonged culture appears
to be an important factor with or without the involvement
of stromal cells. Qui and colleagues ﬁnd enucleation can be
obtained by sequential exposure of CD34+ cells sorted from
FH-B-hTERT/H1coculturetotwosetsofcytokines,followed
by a 2-step 10-day coculture with MS-5 stromal cells [15].
The enucleation eﬃciency varies from 1.5% to 16% for the
day-35 H1/FH-B-hTERT coculture, and 0% for the day-14
H1/FH-B-hTERT coculture. A 3-step culture that involves
a 15-day coculture of H1/mFLSC coculture, followed by a
14-day erythroid burst colony formation, and then a 7-day
liquid culture expansion also produces clusters of enucleated
RBCs with enucleation eﬃciency ranging from 1.3% to
11.4% [13] .Ah i g h e rd e g r e eo fe n u c l e a t i o ni sa c h i e v e db y
Lu et al. with their hemangioblasts protocol composed of
EBformation,hemangioblastexpansion, sequentialcytokine
exposure of the blast cells, and then coculture with human
mesenchymal stem cells (MSCs), with OP9 mouse stro-
mal cells, or without stromal cells [22]. The enucleation
eﬃciencies are 10%–30% without stromal cells, ∼30% on
MSC stromal cells, and 30%–65% on OP9 cells, suggesting
that the presence of stromal cells signiﬁcantly facilitates the
enucleation process. On the other hand, a recent ﬁnding
by Lapillonne and colleagues shows that by supplementing
culture media with human plasma, a signiﬁcant degree
of enucleation is attained without stromal cells in H1
hESCs-derived erythroid cells (52%–66%) [20]. However,
much lower degrees of enucleation (4%–10%) are obtained
with erythroid cells derived from 2 separate hiPSC lines
using the same protocol, suggesting that the reprogramming
process or epigenetic memories retained, may impact the6 Stem Cells International
ability of hiPSC-derived erythroid cells to enucleate. Given
the currently still incomplete eﬃciency of enucleation of
erythroblasts and incomplete lineage determination in vitro
and if these ex vivo generated erythroid cells were to be used
in transfusion, it might be reasonable to ﬁlter them through
conventional leukocyte ﬁlters, followed by irradiation with
3,000cGy,aserythrocytestolerateirradiationwithoutcritical
loss of function.
2.5. Large-Scale Production of Erythroblasts or RBCs from
hESCs or hiPSCs. Several publications have claimed that
their respective protocol results in large-scale generations
of erythroid cells from hESCs or hiPSCs, which is a pre-
requisite of any potential clinical usage. With the H1/FH-
B-hTERT coculture system, Qiu et al. obtain approximately
80 erythroid cells per hESC although it is estimated that
a5 0× 103-fold expansion is achieved by a single CD34+
cells from the coculture [15]. Using H1/mFLSC coculture,
Ma and colleagues generate large erythroid bursts consisting
of ∼0.2 × 106 erythroid cells per burst [13]. Taking into
consideration the colony forming unit frequencies and
further expansion potentials in liquid culture, roughly 1,200
erythroid cells are generated per hESC. A slightly higher
production eﬃciency is achieved by using EB formation
and human plasma supplementation that shows 1,500–3,500
erythroid cells are produced per hESC, but only 200–400
erythroid output per hiPSC [20]. Using recombinant tPTD-
HoxB4 fusion protein and hemangioblast approach, Lu and
colleagues reported the generation of up to 8,000 erythroid
cells per hESC [22]. The highest production eﬃciency
is reported by Dias and colleagues employing the OP9
coculture system, followed by dissociation and reaggregation
on low attachment plates with the addition of cytokines, and
then coculture on MS-5 feeders [8]. Up to 200,000 erythroid
cells are reported to be generated per hESC, and a similar
level of expansion is also obtained with hiPSCs, although
the requirement of murine cells for coculture throughout
the diﬀerentiation procedure, in addition to the signiﬁcantly
longer culture time (70–120 days), remains a setback for
potential clinical applications. Together, these data show that
without signiﬁcant progress in generating erythrocytes from
hESCs or hiPSCs more cost eﬀectively, the magnitude and
cost of replacing donor-derived erythrocytes with these in
vitro generated RBCs will be prohibitive, given that one RBC
concentrate contains approximately 2 × 1012 erythrocytes,
that is, in a country like Germany, 8 × 1018 (1011 per head
of the population) red blood cells are transfused in any given
year.
3. Characterizationof hESC- and
hiPSC-DerivedErythroidCells
3.1. Globin Chain Expression. Amongst all erythroid-
associated characteristics, the globin expression phenotype
has been studied most extensively in the hESC- and hiPSC-
derived erythroid cells. Our laboratory ﬁnds that the α
globin, rather than embryonic ζ globin, is the major α-
locus globin expressed, although expression of ζ globin can
be detected in all erythroid cells from H1 hESC at the
protein level, suggesting a low, but pancellular expression
of embryonic ζ globin [17], diﬀering from the ﬁnding of
Cerdan et al. that shows ζ globin is not expressed by hESC-
derived erythroblasts [16]. The expression of ζ globin is also
conﬁrmed by studies in erythroid cells generated from other
hESC lines as well as H1 line [15, 21, 22, 24], and hiPSCs
originated from either fetal or adult tissues [20]. We ﬁnd
the α/ζ globin ratio does not change whether the erythroid
cells are derived from day-7 or day-14 EBs [17], although
Qiu and colleagues ﬁnd that by extending the coculture
time between hESCs and immortalized human fetal liver
hepatocyte line FH-B-hTERT from 14 days to 35 days, a
lineageswitchoccursandthesehESCs-derivederythroidcells
express α locus globins with an increased α/ζ globin ratio
[15]. Furthermore, individual clonal erythroid expansion
and maturation apparently is accompanied by a maturation
switch characterized by an increasing α/ζ globin ratio over
time as the hESC-derived erythroid cells proceed from the
stage of proerythroblasts to the stage of orthochromatic
erythroblasts [15].
With the exception of the ﬁrst two studies examining
the hematopoietic/erythroid diﬀerentiation of hESC that
claim the adult β globin to be the major globin expressed
by hESC-derived erythroid cells [9, 16], all other studies
followed ﬁnd embryonic ε and fetal γ globins to be the
predominant β-locus globin expressed by these cells, at least
initially, regardless of the diﬀerentiation methods employed
or the ontogenic origin of the hiPSCs [1, 8, 13, 15, 17–
22, 24]. While some studies ﬁnd little changes in ε/γ ratio
in mature erythroid cells derived from diﬀerent time points
of culture [8, 17, 24], Qiu et al. reported that similar to
their ﬁnding in the changes in α/ζ globin ratio, increasing
coculture time also leads to the generation of erythroid cells
expressing mainly fetal γ globin [15]. An increase in the
adult β globin expression with prolonged coculture time
is also observed albeit its expression level is low (∼2% of
all β-locus globins), consistent with the ﬁndings of others
[8, 22, 24]. Interestingly, Ma et al. show a more drastic
increase in β globin expression with their erythroid cells
derived from H1/mFLSC cells coculture. The globin expres-
sion in the erythroid cells of individual clones changes in
a time-dependent manner: embryonic ε-globin-expressing
erythroid cells from individual clones decrease from ∼
100% to ∼50%, whereas adult-type β-globin-expressing cells
increase to ∼100% in all clones examined [13]. It is not
known, however, whether the adult β globin actually is the
major β-locus globin expressed, given that 100% of the
cells are also expressing γ globin, and ∼50% of the cells
are expressing ε globin. Nevertheless, these studies provide
supporting evidence that with prolonged coculture, and/or
prolonged erythroid expansion, the erythroid cells adapt a
more developmentally advanced globin expression pattern.
The transcriptional controls of the globin expression
have not yet been studied in these cells, but a limited number
of studies have been done to analyze the epigenetic landscape
of β globin locus of hESC-derived erythroid cells. It is found
that domains of DNA hypomethylation spanning thousands
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established around the most highly expressed genes during
each developmental stage when comparing hESC-derived
erythroblasts to uncultured FL and bone marrow cells [38,
39]. In addition, our laboratory also ﬁnds that throughout
development, human primary erythroblasts employ simi-
lar histone codes including enrichment of H3K4me3 and
selective depletion of H3K27me1 to ensure proper temporal
expression of speciﬁc globin genes (unpublished data).
Furthermore, a looping mechanism is also at play to bring
the hypersensitive sites of the LCR into physical contact with
the ε globin promoter, presumably to initiate transcription
via the formation of an active chromatin hub, in the ε globin
producing hESC-derived erythroid cells.
3.2. Hemoglobin Analyses and Functionality. As compared to
the globin chains, few studies have been conducted to study
the hemoglobin tetramers in the hESC- or hiPSC-derived
erythroid cells. Using CE-HPLC, it is found that the mature
erythroid cells, derived from both hESCs and iPSCs based on
the EB/human plasma culture system, express mostly HbF
(α2γ2) with little Hb Gower I (ζ2ε2) or Gower II (α2ε2)
[20]. Furthermore, the CO-rebinding kinetics, which probe
the allosteric equilibrium of R and T states, of hemoglobin
from hESC- and hiPSC-derived erythroid cells, are almost
identical to those of cord blood, with or without potent
allosteric eﬀector inositol hexaphosphate, suggesting that the
HbF in these erythroid cells is functional [20]. In addition,
the oxygen dissociation curve of hESC-derived erythroid
cells is displaced to the left, similar to that of the human
cord blood, as compared to that of adult RBCs, consistent
with the higher aﬃnity of HbF to oxygen than HbA [13,
22, 24]. The decreased response to 2,3-diphosphoglycerate
(2,3-DPG)depletionascomparedtoadultRBCsisconsistent
with the lack of interaction between HbF and 2,3-DPG [22].
In addition, hESC-derived erythroid cells also have high
glucose-6-phosphatedehydrogenaseactivity,conﬁrmingthat
they are protected from oxidative damage [13]. Together,
these data indicate that hESC- and hiPSC-derived erythroid
cells will function as oxygen carriers like cord blood or fetal
blood. In contrast, a recent study using the hemangioblast
approach shows that hESC-derived erythroid cells produce
mainly Hb Gower1 (ζ2ε2) with low levels of HbF, Hb
Portland (ζ2γ2), and Hb Gower-2 (α2ε2), each represents
less than 5% of the total hemoglobin [23]. Moreover, these
hemangioblast-derived erythroid cells also have an elevated
amount of Hb Barts (Gγ4) that accounts for 12%–18% of the
total hemoglobin. As Hb Barts has extremely high aﬃnity to
oxygen,thisﬁndingappearstocontradictthepreviousreport
by the same group that hESC-derived erythroid cells have an
oxygendissociationcurveonlyslightlydisplacedtotheleftof
the adult RBCs, and that they show a comparable Bohr eﬀect
at physiologic pH [22]. In addition to not releasing oxygen
into the tissue due to extremely high oxygen aﬃnity, Hb
Barts is moderately insoluble, and therefore accumulates in
theredbloodcells.Hence,thisstudywouldarguethathESC-
derived erythroid cells, despite the large-scale production
using hemangioblast protocol [22], can not be used for
transfusion. The authors do oﬀer that, however, with further
maturation that leads to developmentally more advanced
erythroblasts or enucleated RBCs, the level of Hb Barts may
decrease in these hESC-derived erythroid cells.
4. FutureChallenges
The magnitude and cost of replacing donor-derived erythro-
cyteswithinvitrogeneratedRBCsisprohibitiveandrequires
signiﬁcant progress in the expansion, maturation, and
terminal diﬀerentiation/enucleation of erythrocytes to make
the transfusion products cost eﬀective. A recently published
method of culturing hESCs and hiPSCs in suspension may
aid in the scaling up production of hESCs and hiPSCs
[40]. In addition, the proposed utilization of synthetic
3D structures mimicking bone marrow structure [41]a n d
the manipulation of transcriptional environment, such as
ectopic expression of engineered Nup98-HoxA10 fusion
protein [42] and downregulation of microRNAs-126/125∗
[43], may improve the erythroid production eﬃciency.
However, even if a cost-eﬀective method of generating
erythrocytes from hESCs or hiPSCs were achieved, signif-
icant challenges remain to be met before the therapeutic
use of these cells. While not expressing HLA, mature RBCs
express many surface antigens against which regular (present
in all individuals not expressing the antigen) or irregular
(acquired after contact with the antigen) antibodies can be
directed. Thirty blood group systems, or antigen families,
with almost 400 antigens have been documented, and
antibodies against all of these antigens have been described.
If ignored, such antibodies cause acute, potentially deadly,
or delayed hemolytic transfusion reactions. Therefore, the
presence of such antibodies necessitates selection of antigen-
negative RBCs. Since antigens are expressed from genes
located throughout the genome, any combination of blood
group antigens can occur, thus in theory, an almost inﬁnite
number of hESC or iPSC lines would be required to generate
compatible erythrocytes for all individuals. Generation of
null variants for blood group antigens via genetic manipula-
tion is not conducive as null variants have been described for
many blood group antigens, but all of which are associated
with structural defects and/or with the generation of alter-
native antigens, with the exception of Rh dd (Rh-negative,
the null variant which represents the counter antigen to
Rh D) and O (absence of both A and B transferase). It
may be conceptually reasonable to generate a single hiPSC
line from an O Rh negative ccddee K negative donor
heterozygous for as many antigens as possible (to decrease
foreign antigen dose and hence, antigenicity) and propagate
it in huge biogenerators as a source for nonimmunized
patients. For allo-(poly)sensitized or at risk, chronically
transfusion-dependent patients, speciﬁcally those of rare
bloodtypes,autologousiPSClinescouldbeestablished,from
which individualized erythrocytes could be generated and
stored. It must be stressed, however, that the membrane
protein and glycosylation proﬁle of RBCs produced in vitro,
evenfromautologousiPSClines,maybealteredcomparedto
thatoftheinvivoproducedRBCs,duetothelackofcomplex
environment found in vivo, or an imbalanced transcription
factor expression [44]. The important ﬁnding that iPSCs
and their progeny are rejected in the autologous setting [45]8 Stem Cells International
appropriately brings to the forefront the issue of antigenicity
of ex vivo generated cells due to expression of neoantigens.
It may be plausible to enzymatically remove surface antigens.
However, such approach has not been achieved except for A
and B substances [46].
Furthermore, rigorous studies must be conducted to
fully characterize these in vitro generated RBCs including
their membrane surface potential, pliability, and half-life in
vivo, in addition to proﬁling their hemoglobin packing, gas
exchange properties, and immunogenicities. The sensitivity
ofthesystemiswellillustratedbytherecentevidencethathas
come forth about eﬀects of ageing of erythrocytes on their
therapeutic beneﬁt—free hemoglobin, increased membrane
rigidity, membrane damage, and altered O2 aﬃnity of stored
red cells have all been implicated in adverse outcomes
observed with older erythrocytes [47]. Thus, even after all
the challenges of devising suitable in vitro systems for expan-
sion, maturation and terminal diﬀerentiation/enucleation of
erythrocytes from primitive cell sources have been mastered,
all of these biophysical parameters will still need to be
carefully compared between in vitro and in vivo generated
erythrocytes before they can be used clinically.
5. Conclusions
Signiﬁcant progress has been made in generating erythroid
cells from hESCs and hiPSCs. The production eﬃciency of
up to 200,000 cells per hESC or iPSC has been achieved [8].
Unfortunately, the methodology that generates the highest
number of erythroid cells per hESC is the least deﬁned
and relies heavily on the presence of murine stromal cells:
ﬁrst OP9, then MS-5. The hemoglobin expression pattern
and enucleation eﬃciency are also less clear with erythroid
cells derived from this particular method, than from the
other mass production protocols [13, 20, 22, 23]. Further
investigation of the hemoglobin tetramer composition is
critical, as it is shown that erythroid cells generated from
the protocol with the second-highest production eﬃciency
(8,000 erythroid cells per hESC) have mostly Hb Gower I,
followed by an elevated level of Hb Barts, which would not
be suitable for transfusion [23]. The method proposed by
Lapillonne and colleagues, without using animal products or
stromal cell lines, generates moderate number of erythroid
cells from hESCs (1,500–3,500 erythroid cells per hESC)
that enucleate eﬃciently (∼60%) with functional HbF
tetramers as the major hemoglobin (∼93%). Unfortunately,
this method appears to work less eﬃciently with hiPSC,
whichisimportantsinceoneofthemajorgoalsofgenerating
RBCs is for the transfusion needs of patients with rare blood
phenotypes or those that have been alloimmunized. The
decreased eﬃciency of erythroid generation may be oﬀset
by prescreening for hiPSC lines with increased erythroid
diﬀerentiation propensity, as line-to-line variation has been
documented [18, 19], or by simply increasing the input
number of hiPSCs. Alternatively, generating immortal ery-
throid progenitor lines capable of terminal diﬀerentiation
and enucleation, which have been shown to be successful
in murine ESC-derived cells [48], may be a viable option.
Finally, little is known about these hESC- and hiPSC-derived
erythroidcellsotherthantheirhemoglobincomposition,gas
exchangeproperties,andtheirgrowthandexpansionpattern
in response to various methods. Membrane compositions,
surface antigen expression, immunogenicity, deformability,
and half-life in vivo all require further and vigorous inves-
tigations before the transition from bench to bedside can
occur.
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